tirofiban has been researched along with Diabetes Mellitus in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Dambrink, JHE; Fabris, E; Giannitsis, E; Gosselink, AM; Hamm, C; Hermanides, RS; Koopmans, PC; Ottervanger, JP; Sinagra, G; Ten Berg, JM; van 't Hof, AWJ | 1 |
| Briguori, C; Caccavale, M; D'Andrea, D; Focaccio, A; Golia, B; Librera, M; Ricciarelli, B; Tavano, D; Visconti, G | 1 |
| Dambrink, JH; Dill, T; Hamm, C; Heestermans, AA; Ottervanger, JP; Suryapranata, H; ten Berg, J; Timmer, JR; van 't Hof, AW; van Werkum, JW | 1 |
| Gandhi, PJ; Silva, MA | 1 |
| Baysan, O; Erinc, K; Isik, E; Ozkan, M; Sag, C; Uzun, M; Yokusoglu, M | 1 |
| Le Pen, C; Lilliu, H | 1 |
| Baumann, PQ; Keating, FK; Schneider, DJ; Sobel, BE; Whitaker, DA | 1 |
| Bertrand, M; Demopoulos, LA; DiBattiste, PM; Grines, CL; Harris, KE; Herrmann, HC; Meier, B; Moliterno, DJ; Powers, ER; Roffi, M; Topol, EJ | 1 |
1 review(s) available for tirofiban and Diabetes Mellitus
| Article | Year |
|---|---|
Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2004 |
5 trial(s) available for tirofiban and Diabetes Mellitus
| Article | Year |
|---|---|
NT-proBNP level before primary PCI and risk of poor myocardial reperfusion: Insight from the On-TIME II trial.
Topics: Adult; Aged; Aged, 80 and over; Anterior Wall Myocardial Infarction; Biomarkers; Diabetes Mellitus; Double-Blind Method; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Reperfusion; Natriuretic Peptide, Brain; Peptide Fragments; Percutaneous Coronary Intervention; Prospective Studies; Regression Analysis; ST Elevation Myocardial Infarction; Time-to-Treatment; Tirofiban; Young Adult | 2021 |
Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Male; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Prospective Studies; Recombinant Proteins; Retreatment; Thrombocytopenia; Tirofiban; Tyrosine | 2009 |
Pre-hospital administration of tirofiban in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: a sub-analysis of the On-Time 2 trial.
Topics: Angioplasty, Balloon, Coronary; Coronary Angiography; Diabetes Mellitus; Double-Blind Method; Electrocardiography; Emergency Medical Services; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Tirofiban; Treatment Outcome; Tyrosine | 2010 |
The effect of tirofiban and clopidogrel pretreatment on outcome of old saphenous vein graft stenting in patients with acute coronary syndromes.
Topics: Acute Disease; Clopidogrel; Coronary Disease; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Saphenous Vein; Stents; Ticlopidine; Tirofiban; Tyrosine | 2005 |
Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Coronary Circulation; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Insulin; Integrins; Kinetics; Male; Middle Aged; Neovascularization, Pathologic; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Survival Analysis; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
2 other study(ies) available for tirofiban and Diabetes Mellitus
| Article | Year |
|---|---|
Choice of GPIIb/IIIa antagonist in percutaneous coronary intervention: how should economic criteria be factored in?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cost-Benefit Analysis; Diabetes Mellitus; Drug Costs; Eptifibatide; Hospital Costs; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
Increased ability of tirofiban to maintain its inhibitory effects on the binding of fibrinogen to platelets in blood from patients with and without diabetes mellitus.
Topics: Aged; Diabetes Mellitus; Female; Fibrinogen; Flow Cytometry; Humans; In Vitro Techniques; Male; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2006 |